The Food and Drug Administration today released for public comment a revised draft memorandum of understanding for states regarding interstate distribution of “inordinate amounts” of compounded drugs by licensed pharmacists or physicians. Under the prior draft, issued in 2015 and on which AHA commented, inordinate amounts was defined as equal to or greater than 30 percent of all drug products dispensed or distributed by the compounder. “Some were worried that this provision could impede patients’ access to compounded drugs for which they have a medical need,” said FDA Commissioner Scott Gottlieb, M.D. Under the revised draft, states would agree to identify compounders that distribute more than 50 percent of their total prescription orders for compounded drugs interstate and report certain information to the FDA about those compounders. The draft MOU will be published in the Sept. 10 Federal Register with comments accepted for 90 days.

Related News Articles

Headline
The Food and Drug Administration plans to revise its 2016 draft compounding guidance for hospital and health system pharmacies.
Headline
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
Headline
Members of the pharmaceutical distribution supply chain, including dispensers such as hospitals and pharmacies, can apply through March 11 to participate in a…
Headline
The U.S. District Court for the Western District of Pennsylvania has entered a consent decree prohibiting Ranier’s Rx Laboratory Inc. from manufacturing or…
Headline
The Food and Drug Administration Friday warned physicians and patients who use medical devices to monitor levels of the blood thinner warfarin that certain…
Headline
The AHA today submitted to the Food and Drug Administration legislative, regulatory and best practice recommendations to address new and chronic prescription…